- China
- /
- Life Sciences
- /
- SHSE:603108
Asian Growth Companies With High Insider Ownership In March 2025
Reviewed by Simply Wall St
In March 2025, Asian markets have been navigating a complex landscape marked by global trade tensions and economic policy shifts, with China signaling potential stimulus measures to maintain its growth targets. Amid this backdrop, identifying growth companies with high insider ownership can be an attractive strategy, as such ownership often aligns management's interests with those of shareholders and may indicate confidence in the company's future prospects.
Top 10 Growth Companies With High Insider Ownership In Asia
Name | Insider Ownership | Earnings Growth |
Zhejiang Jolly PharmaceuticalLTD (SZSE:300181) | 23.3% | 26% |
Seojin SystemLtd (KOSDAQ:A178320) | 32.1% | 39.9% |
Laopu Gold (SEHK:6181) | 36.4% | 43.7% |
Global Tax Free (KOSDAQ:A204620) | 20.4% | 89.3% |
Suzhou Sunmun Technology (SZSE:300522) | 35.4% | 92.8% |
Techwing (KOSDAQ:A089030) | 18.8% | 64.3% |
HANA Micron (KOSDAQ:A067310) | 18.3% | 125.9% |
Fulin Precision (SZSE:300432) | 13.6% | 78.6% |
Ascentage Pharma Group International (SEHK:6855) | 17.9% | 60.9% |
Synspective (TSE:290A) | 13.2% | 37.4% |
Let's uncover some gems from our specialized screener.
Kuaishou Technology (SEHK:1024)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Kuaishou Technology is an investment holding company offering live streaming, online marketing, and other services in the People’s Republic of China with a market cap of HK$270.82 billion.
Operations: The company generates revenue from its domestic operations amounting to CN¥119.83 billion and overseas activities contributing CN¥4.25 billion.
Insider Ownership: 19.6%
Kuaishou Technology is experiencing rapid growth, with earnings surging over 1,000% last year and forecasted to grow annually by 16.33%, outpacing the Hong Kong market. The company trades at a good value compared to peers, priced 22.1% below its fair value estimate. Recent innovations like Kling AI's multi-image reference feature enhance creative capabilities and expand monetization efforts, while insider ownership remains stable without substantial recent trading activity.
- Dive into the specifics of Kuaishou Technology here with our thorough growth forecast report.
- The valuation report we've compiled suggests that Kuaishou Technology's current price could be quite moderate.
BYD (SEHK:1211)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: BYD Company Limited, along with its subsidiaries, operates in the automobiles and batteries sectors across China, Hong Kong, Macau, Taiwan, and internationally, with a market cap of HK$1.13 trillion.
Operations: BYD's revenue is primarily derived from its automobiles and batteries segments, operating across the People's Republic of China, Hong Kong, Macau, Taiwan, and international markets.
Insider Ownership: 28.8%
BYD demonstrates strong growth potential, with earnings expected to grow at 17.8% annually, surpassing the Hong Kong market's average. Recent production volumes reflect significant increases compared to last year, underscoring robust operational expansion. The recent HK$43.51 billion follow-on equity offering supports further growth initiatives. BYD's strategic expansion in the UK and energy storage projects in Nebraska highlight its commitment to innovation and sustainability, though insider trading activity remains minimal over the past three months.
- Navigate through the intricacies of BYD with our comprehensive analyst estimates report here.
- Upon reviewing our latest valuation report, BYD's share price might be too optimistic.
Shanghai Runda Medical Technology (SHSE:603108)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Shanghai Runda Medical Technology Co., Ltd. operates in the medical technology sector and has a market cap of approximately CN¥14.06 billion.
Operations: Shanghai Runda Medical Technology Co., Ltd. generates its revenue through various segments in the medical technology sector.
Insider Ownership: 16%
Shanghai Runda Medical Technology shows promising growth prospects, with earnings expected to grow significantly at 67.2% annually, outpacing the Chinese market's average. Despite a volatile share price and declining profit margins, the company trades at good value relative to its peers. Revenue is projected to increase by 13.6% per year, slightly above market expectations. While insider trading data over the past three months is unavailable, substantial insider ownership aligns interests with shareholders' long-term goals.
- Get an in-depth perspective on Shanghai Runda Medical Technology's performance by reading our analyst estimates report here.
- Our valuation report here indicates Shanghai Runda Medical Technology may be undervalued.
Where To Now?
- Access the full spectrum of 637 Fast Growing Asian Companies With High Insider Ownership by clicking on this link.
- Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
- Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
If you're looking to trade Shanghai Runda Medical Technology, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentNew: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SHSE:603108
Shanghai Runda Medical Technology
Shanghai Runda Medical Technology Co., Ltd.
Reasonable growth potential and fair value.
Market Insights
Community Narratives
